1. Introduction {#sec1-medicina-55-00711}
===============

Pulmonary hypertension (PH) is related to poor outcomes regardless of surgical or interventional treatment in aortic stenosis (AS) patients \[[@B1-medicina-55-00711],[@B2-medicina-55-00711],[@B3-medicina-55-00711]\]. Therefore, an evaluation of the risk factors for the development of PH in this group of patients is of great importance to improve risk stratification. Several studies have evaluated the echocardiographic predictors for the genesis of PH in AS \[[@B4-medicina-55-00711],[@B5-medicina-55-00711]\]. Nevertheless, data about the impact of cardiac magnetic resonance (CMR) derived parameters are still lacking. Modern CMR imaging techniques may provide accurate measurements of cardiac chambers, as well as about the progression of myocardial fibrosis, and, combined with feature tracking (CMR-FT), helps to detect early subclinical ventricular dysfunction \[[@B6-medicina-55-00711],[@B7-medicina-55-00711],[@B8-medicina-55-00711],[@B9-medicina-55-00711]\]. A large number of studies using CMR investigated a variety of left (LV) and right ventricular (RV) structural and functional parameters in pre-capillary PH patients, as well as their prognostic significance \[[@B10-medicina-55-00711],[@B11-medicina-55-00711],[@B12-medicina-55-00711]\]. However, there is still scarce information about the LV structure and function in PH with AS. Thus we aimed to evaluate the LV size, function and mechanics in patients with isolated severe AS and PH using novel CMR technique as well as to investigate the impact of these parameters on elevated pulmonary systolic pressure (sPAP).

2. Materials and Methods {#sec2-medicina-55-00711}
========================

2.1. Study Population {#sec2dot1-medicina-55-00711}
---------------------

The study included 30 patients with symptomatic severe AS, defined as an aortic valve area less than or equal to 1 cm², who underwent an 2D-echocardiography (2D echo) and CMR evaluation before aortic valve replacement surgery. The patients were divided into two groups according to the presence or absence of PH, with an sPAP cut-off value of 45 mm Hg derived by 2D echo. The patients with documented coronary heart disease, chronic pulmonary disease, atrial fibrillation, and moderate or severe mitral regurgitation were excluded from the study.

The study was approved by the Kaunas Regional Biomedical Research Ethics Committee, no. BE-2-8, issued on 29 October 2014. All of the patients gave their informed written consent.

2.2. Transthoracic Echocardiography {#sec2dot2-medicina-55-00711}
-----------------------------------

The 2D echo was performed using a GE Vivid 7 system (GE Vingmed Ultrasound AS N-3190, Horten, Norway), by an independent, experienced echocardiographer. Digital loops were stored and analyzed offline (EchoPac V.6.0.0; GE Vingmed, Chalfont St. Giles, United Kingdom).

A conventional 2D echo was performed from the left parasternal and apical windows. Echocardiographic LV and aortic valve area measurements were performed according to the American Society of Echocardiography recommendations \[[@B13-medicina-55-00711]\]. PH was defined as an estimated sPAP of ≥45 mm Hg, based on a tricuspid regurgitation flow velocity of ≥3.0 m/s and on the presence of other echocardiographic PH signs \[[@B14-medicina-55-00711]\].

2.3. Cardiac Magnetic Resonance Imaging Measurements {#sec2dot3-medicina-55-00711}
----------------------------------------------------

CMR was performed using a 1.5T whole-body system (Siemens Aera, Siemens Medical Solutions; Erlangen, Germany). The CMR protocol consisted of an ECG gated cine sequence obtained during a short breath-hold. The cine views were obtained in three LV long (two, three, and four chambers) and short axis views. The end-diastole and end-systole of the LV were defined as the maximum and minimum volumes on balanced steady-state free precession (bSSFP) sequences.

The end-diastolic volume (EDV), end-systolic volume (ESV), myocardial mass (MM), and ejection fraction (EF) of LV were calculated in standard cine images using an MR analysis software system (syngo.via; Siemens Healthcare, Erlangen, Germany. The indices of the LV volumes (EDVi and ESVi) and myocardial mass index (MMi) were calculated based on the body surface area.

The LV fibrosis expansion was assessed using a late gadolinium enhancement (LGE) sequence. The LGE images were obtained 10 minutes after the infusion of gadolinium (0.2 mmol/kg). The LV fibrosis extent was assessed using a CMR analysis software system (syngo.via; Siemens Healthcare). To assess the midwall LGE quantitatively, short-axis slices were inspected visually, the area of LGE was traced manually, and the fibrosis area results were expressed as a percentage of the myocardial mass.

2.4. Feature Tracking Analysis {#sec2dot4-medicina-55-00711}
------------------------------

The CMR images were analyzed by two experienced radiologists using a commercial FT software package (Medis Suite QStrain 2.0; Medis Medical Imaging Systems B.V., Leiden, The Netherlands). The endocardial contours of LV end-diastole and end-systole were marked semi-automatically throughout the cardiac cycle on standard CMR balanced steady-state free precession (bSSFP) sequences. The contours were manually corrected, if necessary. The LV global longitudinal strain (GLS) was calculated by averaging the strain curves of two-, three-, and four-chamber long-axis views. The LV global circumferential strain (GCS) was calculated by averaging the strain curves of the basal, mid, and apical segments obtained from the short-axis views.

2.5. Statistical Analysis {#sec2dot5-medicina-55-00711}
-------------------------

The continuous variables were expressed as the median (interquartile range), and the categorical variables were described as a percentage (number). The continuous variables distribution was verified using the Shapiro--Wilk test. The Mann--Whitney test was used to compare the quantitative sizes of two independent samples. The correlations were computed using Spearman's method. Chi-square (Fisher's Exact Test) tests were used to compare the frequencies of the qualitative variables. The results were considered statistically significant when the two-tailed *p*-value was \<0.05.

The incremental value of the CMR variable in predicting the development of sPAP ≥ 45 mm Hg was assessed in terms of the construction of the receiver--operating characteristic (ROC) curves. All of the statistical analyses were performed with SPSS 23.0 software (SDSPSS, Chicago, IL, USA).

3. Results {#sec3-medicina-55-00711}
==========

Thirty symptomatic patients (mean age 70 (64--75) years) with severe AS (aortic valve area ≤1 cm²) were prospectively enrolled in the study. Among all of the patients, seven (23%) had PH (mean sPAP 55 ± 6.6 mm Hg). The clinical, echocardiographic, and demographic characteristics of the overall cohort, and those with and without PH are shown in [Table 1](#medicina-55-00711-t001){ref-type="table"}.

The patients in both groups were similar in terms of age, sex, and body mass index. The groups did not differ in terms of the New York Heart Association (NYHA) functional class and with the prevalence of comorbidities such as arterial hypertension, diabetes mellitus, and renal insufficiency. The aortic valve area did not differ between the groups.

LV EF, estimated by 2D echo and CMR, did not differ between the groups, and was not related to PH (*p* \> 0.05; [Table 1](#medicina-55-00711-t001){ref-type="table"} and [Table 2](#medicina-55-00711-t002){ref-type="table"}). The LV MM and MMi, obtained by CMR, did not differ between the groups, and was also not associated with elevated sPAP (*p* \> 0.05). For LV EDV and EDVi, ESV, and ESVi, the LV fibrosis area was significantly larger in the PH group when compared to the AS patients without PH (*p* \< 0.05) ([Table 2](#medicina-55-00711-t002){ref-type="table"}). The LV GLS and GCS was lower in patients with elevated sPAP (*p* = 0.004) ([Table 2](#medicina-55-00711-t002){ref-type="table"}).

Increased sPAP (≥45 mm Hg) correlated with LV EDVi (*r* = 0.6, *p* \< 0.000), LV GLS (*r* = 0.5, *p* = 0.007), and LV fibrosis (*r* = 0.6, *p* = 0.004), however it did not correlate with LV EF (*r* = −0.3, *p* = 0.206) and LV GCS (*r* = 0.4, *p* = 0.052).

The ROC analysis data showed that increased LV EDVi \> 107.7 mL/m², severely reduced LV GLS \> −14.2% and extended LV fibrosis \>5% (with a sensitivity of 100% and a high specificity) may predict the development of pulmonary hypertension in severe AS patients ([Table 3](#medicina-55-00711-t003){ref-type="table"}, [Figure 1](#medicina-55-00711-f001){ref-type="fig"}).

4. Discussion {#sec4-medicina-55-00711}
=============

Our study evaluated the changes of LV size, morphology, function, and mechanics in patients with severe AS, and found that a larger LV end-diastolic volume, impaired LV global longitudinal strain, as well as more significant larger LV fibrosis extent derived by CMR are predictors of the development of PH in severe AS patients.

Increased afterload in severe AS is the leading cause of LV hypertrophy \[[@B15-medicina-55-00711]\]. All of our patients with severe AS had increased LV MMi (compared with the normal range, according to the guidelines \[[@B13-medicina-55-00711]\]. However, our data demonstrated that increased LV MMi was not related to elevated sPAP (*p* = 0.52), probably because a higher LV mass reflects a normal adaptation to an increase in pressure overload, or maybe our PH study group was too small to reflect changes.

In the end-stage of the hypertrophic process, LV dilatation can be observed in AS patients \[[@B15-medicina-55-00711]\]. In our study, LV EDV and ESV were significantly increased in the PH group (*p* \< 0.001). Lancellotti et al. confirmed that the LV EDV measured by 2D echocardiography could be a predictor of exercise PH in asymptomatic severe AS \[[@B4-medicina-55-00711]\]. However, the data concerning CMR derived LV end-diastolic and end-systolic volumes for PH prediction in severe AS is lacking. We found LV EDVi to be a predictor of PH in severe AS, but it is not an early indicator, as it is found in the late phase of the disease, reflecting the pathological remodeling of the ventricle.

In our study, patients had a normal or slightly reduced LV EF, while a significant correlation between LV EF and elevated sPAP was not found. This data coincides with other studies demonstrating that the LV systolic function was not also associated with PH in AS \[[@B16-medicina-55-00711],[@B17-medicina-55-00711]\]. However, previous studies showed that LV EF is not an accurate parameter to appreciate systolic impairment in AS, and can even overestimate it in the presence of concentric LV hypertrophy \[[@B18-medicina-55-00711]\]. Therefore, the detection of early LV dysfunction before changes of LV EF is of great importance, and it becomes possible using new imaging techniques such as feature tracking (FT) CMR.

The longitudinal LV global strain is influenced by LV overload, hypertrophic remodeling, and chamber dimensions, and first begins to decline when the LV EF is maintained \[[@B19-medicina-55-00711]\]. Our FT-CMR study determined that the worsening of CMR LV GLS was the major independent predictor of PH in severe AS, and this parameter could be the earliest predictor of sPAP elevation. Other studies using echocardiography have identified similar results, that a reduced LV global longitudinal strain in AS was associated with PH \[[@B19-medicina-55-00711]\].

Previous research studies indicated that LV EF is related mainly to the global radial LV function. When LV EF begins to decrease, a gradual loss of circumferential shortening can be observed \[[@B20-medicina-55-00711],[@B21-medicina-55-00711]\]. Nevertheless, our study showed lower LV GCS within PH group which correlated with LV EF (*r* = 0.6, *p* = 0.01) and LV volume (*r* = −0.7, *p* = 0.01, however it did not correlate with PH, probably mainly due to the small sample size

AS is accompanied by the progressive development of interstitial fibrosis, followed by replacement fibrosis. Late gadolinium enhancement (LGE) is a well-established imaging method to detect myocardial fibrosis in AS \[[@B9-medicina-55-00711]\]. Several studies analyzed that replacement fibrosis detected by LGE is a strong predictor of poor outcome \[[@B22-medicina-55-00711],[@B23-medicina-55-00711]\]. However, the data about the myocardial fibrosis impact on PH development is lacking. We analyzed the extent of replacement fibrosis, and revealed that LV fibrosis was significantly higher in the PH group, and a significant correlation between LV fibrosis and elevated sPAP was determined.

Larger scale studies using CMR and CMR-FT are needed in severe AS with PH patients, in order to assess the changes of the ventricles size, morphology, function, and their association with elevated sPAP. Evaluation of these risk factors for the development of PH in this group of patients is critical to improve the risk stratification. These findings could help to select the patients who would benefit from earlier surgery before the PH development.

5. Conclusions {#sec5-medicina-55-00711}
==============

In patients with severe aortic stenosis, a larger end-diastolic LV volume, impaired LV global longitudinal strain, and larger LV fibrosis extent can predict the development of pulmonary hypertension.

The main limitation of this study was the small sample size. Patients with documented coronary heart disease or chronic obstructive pulmonary disease, atrial fibrillation, and moderate--severe mitral regurgitation were excluded from the study. Hence, the findings cannot be extrapolated to these patient groups. The pulmonary pressures were not measured by invasive cardiac catheterization, but earlier studies showed that the echocardiographic estimation of sPAP correlates well with invasive measurements \[[@B24-medicina-55-00711]\].
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medicina-55-00711-t001_Table 1

###### 

Demographic, clinical, and echocardiographic parameters of patient cohort.

  Characteristic                                Overall (*n* = 30)    sPAP ≥ 45 mm Hg (*n* = 7)   sPAP \< 45 mm Hg (*n* = 23)   *p*-value
  --------------------------------------------- --------------------- --------------------------- ----------------------------- -----------
  Age, years                                    70 (64--75)           73 (60--75)                 70 (65--76)                   0.883
  Sex, male/female, *n* (%)                     16 (53.3)/14 (46.7)   4 (57.1)/3 (42.9)           12 (52.2)/11(47.8)            1.0
  Arterial hypertension, *n* (%)                25 (83.3)             6 (85.7)                    19 (82.3)                     1.0
  Diabetes mellitus, *n* (%)                    2 (6.7)               0                           2 (6.7)                       1.0
  NYHA functional class 2--3, *n* (%)           26 (86.7)             6 (85.7)                    20 (87.0)                     1.0
  Body mass index, kg/m^2^                      28.5 (25.0--32.30)    27.0 (22.0--32.0)           29.0 (25.0--33.0)             0.349
  Glomerulal filtration rate, mL/min/1.73 ^2^   83.5 (65.0--101.0)    74.0 (58.0--83.0)           87.0 (65.0--106.0)            0.077
  Aortic valve area, cm^2^                      0.85 (0.64--0.96)     0.87 (0.75--0.95)           0.8 (0.63--1.0)               0.571
  Mean aortic gradient (mm Hg)                  43 (40--46)           42 (40--45)                 43 (40--46)                   0.708
  sPAP, mm Hg                                   37.5 (35.5--43.8)     57.0 (49.0--63.0)           36.0 (33.0--41.0)             \<0.001
  LV end-diastolic diameter index, mm/m^2^      25.5 (22.8--29.3)     30.0 (29.0--32.0)           24.0 (22.0--27.0)             0.003
  LV EF (%)                                     55.0 (50.0--55.0)     50.0 (40.0--55.0)           55.0 (50.0--55.0)             0.809

Values are expressed as number (%) or median (interquartile range); NYHA---New York Heart Association; sPAP---systolic pulmonary arterial pressure; LV---left ventricular; EF---ejection fraction.

medicina-55-00711-t002_Table 2

###### 

Left ventricular measurements: magnetic resonance imaging and feature tracking parameters.

  ------------------------------------------------------------------------------
  Parameter        sPAP ≥ 45 mm Hg\         sPAP \< 45 mm Hg\        *p*-value
                   (*n* = 7)                (*n* = 23)               
  ---------------- ------------------------ ------------------------ -----------
  LV EDV, mL       289.0 (245.0--337.0)     179.4 (159.0--200.4)     \<0.001

  LV EDVi, mL/m²   140 (120.0--160.0)       90.0 (82.5--103.0)       \<0.001

  LV ESV, mL       109 (94--111)            59 (50--84)              \<0.001

  LV ESVi, mL/m²   55 (55--60)              32 (27--36)              \<0.001

  LV MM, g         235.0 (180.0--263.0)     197.0 (141.1--306.0)     0.54

  LV MMi, g/m^2^   121 (108--148)           103 (82--140)            0.26

  LV EF, %         51.5 (42.2--64.3)        61.5 (47.0--68.3)        0.23

  LV GLS, %        −14.0 (−14.9--(−8.9))    −21.1 (−23.4--(−17.8))   0.004

  LV GCS, %        −16.4 (−15.4--(−10.9))   −32.0 (−36.1--(−20.8))   0.004

  LV fibrosis, %   7.8 (5.6--8.0)           1.3 (1.2--1.48)          0.005
  ------------------------------------------------------------------------------

LV---left ventricular; ESV---end-systolic volume; ESVi---end-systolic volume index; EDV---end-diastolic volume; EDVi---end-diastolic volume index; MM---myocardial mass; MMi---myocardial mass index; EF---ejection fraction; GLS---global longitudinal strain; GCS---global circumferential strain.

medicina-55-00711-t003_Table 3

###### 

Receiver--operating characteristic (ROC) analysis data. Cardiac magnetic resonance (CMR) parameters in the prediction of elevated sPAP (≥45 mm Hg).

  ----------------------------------------------------------------------------------------
  Parameters/Threshold     Area under Curve (95% CI)   Sensitivity (%)   Specificity (%)
  ------------------------ --------------------------- ----------------- -----------------
  LV EDVi \> 107.7 mL/m²   95.7\                       100               87
                           (88.9--102)                                   

  LV LGS \> −15.5%         86.3\                       100               82.6
                           (73.0--99.7)                                  

  LV fibrosis \> 5%        89.3\                       100               91.7
                           (69.3--109.3)                                 
  ----------------------------------------------------------------------------------------
